BRAF and neoplasm: The BRAF V600E mutation constitutively activates the MAPK/ERK pathway, an oncogenic signaling pathway that promotes the proliferation of SOX2+ embryonic cells, transforming them into tumor-initiating cells and stimulating processes such as angiogenesis and apoptosis inhibition (23, 24) (Figure 2).